FY2024 Earnings Forecast for CKPT Issued By HC Wainwright

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) – Stock analysts at HC Wainwright decreased their FY2024 earnings per share (EPS) estimates for shares of Checkpoint Therapeutics in a report released on Thursday, November 14th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings of ($0.94) per share for the year, down from their previous estimate of ($0.80). HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Checkpoint Therapeutics’ current full-year earnings is ($0.91) per share. HC Wainwright also issued estimates for Checkpoint Therapeutics’ Q4 2024 earnings at ($0.22) EPS.

Checkpoint Therapeutics Stock Performance

CKPT opened at $3.30 on Monday. The stock’s 50 day moving average price is $2.84 and its 200-day moving average price is $2.37. Checkpoint Therapeutics has a one year low of $1.36 and a one year high of $3.97. The stock has a market cap of $148.56 million, a price-to-earnings ratio of -1.79 and a beta of 1.23.

Checkpoint Therapeutics (NASDAQ:CKPT) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.08).

Hedge Funds Weigh In On Checkpoint Therapeutics

Several hedge funds have recently bought and sold shares of the business. XTX Topco Ltd purchased a new stake in shares of Checkpoint Therapeutics during the second quarter valued at $34,000. Gladstone Institutional Advisory LLC boosted its position in Checkpoint Therapeutics by 141.4% in the 3rd quarter. Gladstone Institutional Advisory LLC now owns 35,000 shares of the company’s stock valued at $78,000 after buying an additional 20,500 shares during the period. Magnus Financial Group LLC increased its position in shares of Checkpoint Therapeutics by 12.9% during the third quarter. Magnus Financial Group LLC now owns 35,000 shares of the company’s stock worth $78,000 after acquiring an additional 4,000 shares during the period. 180 Wealth Advisors LLC bought a new stake in shares of Checkpoint Therapeutics during the second quarter valued at approximately $96,000. Finally, Choreo LLC boosted its holdings in shares of Checkpoint Therapeutics by 12.2% in the second quarter. Choreo LLC now owns 65,002 shares of the company’s stock valued at $133,000 after purchasing an additional 7,080 shares during the period. Institutional investors own 22.00% of the company’s stock.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.